newsfilter
← Latest News
Business Wire·

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer's Population

Target engagement and biomarker data expands understanding of the role of P. gingivalis and the potential benefit of lysine gingipain inhibition Biomarker data and correlations to clinical outcomes consistent with the gingipain hypothesis Cortexym